AEON Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
AEON$0.18-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
(in thousands, except share and per share data) (Unaudited)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Six Months Ended | ||||||||||||
| · · June 30, · · June 30, | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| Operating expenses: · · · · · · · · · · | ||||||||||||
| Selling, general and administrative | | $2,991 | | $3,258 | | $6,893 | | $6,383 | ||||
| Research and development | | 2,938 | | 1,064 | | 4,973 | | 1,889 | ||||
| Change in fair value of contingent consideration | | (10) | | 16 | | (15) | | (3,472) | ||||
| Total operating costs and expenses | | 5,919 | | 4,338 | | 11,851 | | 4,800 | ||||
| Loss from operations | | (5,919) | | (4,338) | | (11,851) | | (4,800) | ||||
| Other (loss) income: | | | | | | | | | ||||
| Change in fair value of convertible notes | | (213) | | (1,854) | | (8,940) | | (3,485) | ||||
| Change in fair value of warrants | | 4,941 | | (542) | | 9,597 | | 86,187 | ||||
| Loss on issuance of warrants | | | — | | | — | | | — | | (75,644) | |
| Loss on extinguishment of debt | | | — | | | — | | | (76) | | — | |
| Loss on derivative liability | | | — | | | — | | | (1,743) | | | — |
| Other income, net | | 36 | | 92 | | 65 | | 195 | ||||
| Total other (loss) income, net | | 4,764 | | (2,304) | | (1,097) | | 7,253 | ||||
| (Loss) income before taxes | | (1,155) | | (6,642) | | (12,948) | | 2,453 | ||||
| Income taxes | | — | | — | | — | | — | ||||
| Net (loss) income | | $(1,155) | | $(6,642) | | $(12,948) | | $2,453 | ||||
| Basic net (loss) income per share | | $(0.02) | | $(0.60) | | $(0.28) | | $0.32 | ||||
| Diluted net (loss) income per share | | $(0.02) | | $(0.60) | | $(0.28) | | $0.31 | ||||
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | | | 50,530,946 | | | 11,090,809 | | | 45,599,911 | | | 7,557,472 |
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | | 50,530,946 | | 11,090,809 | | 45,599,911 | | 7,848,566 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.